Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a ...
The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.
A research team has established a virus-induced gene silencing (VIGS) system in taro, enabling researchers to rapidly verify ...
Purespring’s gene therapy, PS-002, uses a viral vector to target kidney cells—known as podocytes—to treat IgA nephropathy, a ...
Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...
RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.
In 2022, Opus Genetics signed an agreement with National Resilience for developing and manufacturing AAV vector-based gene ...
In this GEN webinar, Andrea O'Hara, PhD, a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use ...
It is administered as a single-dose recombinant adeno-associated virus rhesus isolate serotype 74 (rAAVrh74) vector-based gene transfer therapy. After an initial accelerated approval decision in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback